PDL eTechnology Update ePocrates and Web PA Overview for PDLIAG Implementation Advisory Group June...

Post on 20-Jan-2016

215 views 0 download

Tags:

transcript

PDL eTechnology Update

ePocrates and Web PA

Overview for PDLIAG Implementation Advisory GroupJune 22, 2004

CONFIDENTIAL: This document contains proprietary ideas, concepts, and other information which belong exclusively to ePocrates, Inc. Information disclosed herein should be considered proprietary and confidential. This document is the property of ePocrates Inc. and may not be disclosed, distributed, or reproduced without the express written consent of ePocrates, Inc.

1800 Gateway Drive, San Mateo, CA 94404

Phone: 650-227-1700 Fax: 650-227-2770

Scheduled for Implementation September 1, 2004

350,000 active subscribers

8,300 in Virginia

140,000 (20%) physicians active subscribers

3,800 (23%) in Virginia

600 new users per day

A new physician joins every 14 minutes

68% of MDs with PDA have ePocrates

Over 20% of All U.S. Physicians Over 20% of All U.S. Physicians Currently Subscribe to ePocratesCurrently Subscribe to ePocratesOver 20% of All U.S. Physicians Over 20% of All U.S. Physicians Currently Subscribe to ePocratesCurrently Subscribe to ePocrates

Blue Shield of California

Michigan Dept of Community Health

ePocrates PartnershipsMore than 90 Clients representing 85 million livesePocrates PartnershipsMore than 90 Clients representing 85 million lives

Overview of ePocrates Rx® Features

Formulary menu

Drug nameFormulary status codes

Drug reference guide

Drug Information Formulary Information

MultiCheck™AutoUpdate

Do Physicians Value ePocrates Do Physicians Value ePocrates Formulary Offering?Formulary Offering? 73%1 reported that the application improved workflow efficiency in

the practice because it decreased their reliance on formulary books and reduced the formulary-related pharmacy phone calls.

65%1 said that they provided a better quality of care since they were more likely to reference drug information before prescribing.

78%1 reported that the application is likely to influence their choice of prescription medications as it allows them to avoid pharmacy phone calls and offer patients a lower copay.

74%2 were unaware of formulary status changes in a timely manner, prior to using the application.

79%2 were “more likely to have a favorable impression of a health plan that lists its formulary information in ePocrates Rx Formulary than a health plan that does not.”

1 AdvancePCS–ePocrates Outpatient Study, September 2000. 2 ePocrates User Survey, June 2002 (939 respondents)

Benefits to the Commonwealth of VirginiaBenefits to the Commonwealth of VirginiaBenefits to the Commonwealth of VirginiaBenefits to the Commonwealth of Virginia

Increase beneficiary satisfaction and quality of care

Manage rising administrative and drug costs

Improve provider relations through less administrative hassle

Why should physicians use ePocrates Rx®?

50% of MDs estimated that using ePocrates Rx® has prevented on average at least 1 ADE on a weekly basis

65% rate high or very high the impact of the application on quality of care

73% of physicians rate high or very high the impact of the application on workflow efficiency in the practice2

Prior to using ePocrates Rx® with the formulary feature, 74% of physicians were unaware of formulary status changes in a timely manner3

Improve quality of care Improve workflow efficiency

PDL Web Prior Authorization (PA)

Internet Based Technology

PDL Web PA is a web based application.

It was developed in an effort to provide

authorized users with a web tool that will

enhance the process of submitting prior

authorizations.

Ease of Use

Batch PA Requests

Check Status of Submitted PAs

Monitoring for Renewals

Review Drug Therapy Alternatives

Advantages of Web PA System

Pediatrics

Family Practice Physicians

Long-Term Care Pharmacy

Internal Medicine Physicians

Academic Health Care Center

Beta Test Sites

My PAs is a summary screen of PA requests made through the web

View of a PA Request

View of Alternative Drug Therapy